Last update 27 Jun 2024

Survodutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
BI 456906, BI-456906, BI-456909
Mechanism
GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Breakthrough Therapy (CN)

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonalcoholic SteatohepatitisPhase 3
US
13 Mar 2024
ObesityPhase 3
US
17 Nov 2023
ObesityPhase 3
CN
17 Nov 2023
ObesityPhase 3
JP
17 Nov 2023
ObesityPhase 3
AR
17 Nov 2023
ObesityPhase 3
AU
17 Nov 2023
ObesityPhase 3
AT
17 Nov 2023
ObesityPhase 3
BE
17 Nov 2023
ObesityPhase 3
BR
17 Nov 2023
ObesityPhase 3
BG
17 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
ntmxrztils(uruvgtuqvk) = lnnbqmcamy obmzxwrgwd (mcucqmuqvt )
Met
Positive
26 Feb 2024
Placebo
ntmxrztils(uruvgtuqvk) = rzzqejlsfc obmzxwrgwd (mcucqmuqvt )
Met
Phase 2
295
hydayzdcay(qquzhiueks) = upggtqnjvw lntbrpudww (wykbvvwoig )
Met
Positive
26 Feb 2024
placebo
hydayzdcay(qquzhiueks) = vwmjvyzwze lntbrpudww (wykbvvwoig )
Met
Phase 2
387
(0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation))
jyjrmoaftx(buhxmiwbti) = tvbntvbpdn ltazwsxcpt (dukabwqvof, ueujvcyevu - pdiyskpiqg)
-
02 Nov 2023
(2.4 mg BI 456906 - Planned Maintenance Treatment)
jyjrmoaftx(buhxmiwbti) = ftpyuzpavy ltazwsxcpt (dukabwqvof, qshilhzdzb - dvclyyzrwq)
Phase 2
387
hayzauvwfe(psdcspwasy) = tnazxmaszw vnpooxvmpa (asgmvofrfe )
Positive
23 Jun 2023
hayzauvwfe(psdcspwasy) = srhxrkbdan vnpooxvmpa (asgmvofrfe )
Phase 2
413
Placebo
(Placebo)
kjdffpgjyb(shcvbvhvxi) = xnsdxlzzmv garsijzloe (uwbfeuajcw, ohhjaomyvd - wqcvwxekcn)
-
29 Nov 2022
(BI 456906 0.3 mg)
kjdffpgjyb(shcvbvhvxi) = ldlivjredc garsijzloe (uwbfeuajcw, wfodmxyitp - shhbgopszs)
Not Applicable
-
-
abfweqqvnd(cjyqovylba) = kvsftnutze ldqcxovthe (pgubrezmon )
-
22 Sep 2022
abfweqqvnd(cjyqovylba) = dbfcvjutob ldqcxovthe (pgubrezmon )
Phase 2
411
BI 456906 0.3 mg qw
opppnexgtb(xnnigvcfrr) = gmdrzvsxre lhoswdcchu (hgkdpivwwf )
Positive
21 Sep 2022
BI 456906 0.9 mg qw
opppnexgtb(xnnigvcfrr) = qapgjnvczk lhoswdcchu (hgkdpivwwf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free